Slaughter and May is advising GHO Capital Partners, the European specialist investor in global healthcare, on the sale of VISUfarma to Lupin, the global pharmaceuticals company.
VISUfarma was created by GHO Capital in 2016 by combining the founder-owned Italian VISUfarma with the European commercial operations of Nicox S.A.. Since its initial investment as part of Fund I, GHO has grown the business substantially into a pan-European leader of ophthalmology pharmaceuticals.
Completion of the transaction is conditional upon receipt of certain regulatory approvals and is expected to occur by the end of 2025.
Private Equity and Corporate
Harry Bacon
Partner
Claire Jackson
Partner
Jack Hull
Associate
Nida Naqvi
Associate
Lisa McKeown
Associate
Tax
Charles Osborne
Partner
Amy Motherwell
Associate